# Rituximab to Treat Neuropathy With Anti-MAG Antibodies

> **NCT00050245** · PHASE2 · COMPLETED · sponsor: **National Institute of Neurological Disorders and Stroke (NINDS)** · enrollment: 30 (—)

## Conditions studied

- Polyneuropathies

## Interventions

- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT00050245
- **Lead sponsor:** National Institute of Neurological Disorders and Stroke (NINDS)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-11-27
- **Primary completion:** —
- **Final completion:** 2007-10-17
- **Target enrollment:** 30 (—)
- **Last updated:** 2017-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00050245

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00050245, "Rituximab to Treat Neuropathy With Anti-MAG Antibodies". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00050245. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*